Managing DME When Anti-VEGF Response Is Limited - Takeaways - MDSpire

Managing DME When Anti-VEGF Response Is Limited

Retina Minute: Drs. Kuppermann and Singer discuss week-12 findings from the ERLYDEX trial in anti-VEGF suboptimal responders

  • By

  • Baruch D. Kuppermann, MD, PhD

  • Michael A. Singer, MD

  • March 1, 2026

  • 5 min

Share

  • 1

    The ERYLDEX study evaluated the effectiveness of switching to dexamethasone implant in DME patients with inadequate anti-VEGF response.

  • 2

    Patients switched to DEX-I improved vision by approximately 8 letters, while those on anti-VEGF showed no vision gain.

  • 3

    Switching to DEX-I resulted in a significant reduction in central subfield thickness, improving by over 120 µm by week 12.

  • 4

    Fifty percent of patients switched to DEX-I gained 10 letters compared to only 6% on anti-VEGF therapy.

  • 5

    The study suggests earlier switching to DEX-I after 3 anti-VEGF injections may prevent vision loss in DME patients.

Original Source(s)

Managing DME When Anti-VEGF Response Is Limited

  • by Baruch D. Kuppermann, MD, PhD, Michael A. Singer, MD

  • March 1, 2026

Related Content

Subtle changes in the outer retinal and choroidal structures in individuals at elevated risk for advancing to age-related macular degeneration

Searching for the Spectral Signature of Alzheimer’s

Could a tri-spectral retinal imaging module offer new hopes for Alzheimer’s disease screening?

  • February 6, 2026

  • 2 min
Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks